

Ruth Plummer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7232132/publications.pdf>

Version: 2024-02-01

42
papers

2,074
citations

361413

20
h-index

289244

40
g-index

44
all docs

44
docs citations

44
times ranked

3152
citing authors

#	ARTICLE	IF	CITATIONS
1	A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2022, 163, 19-26.	2.0	19
2	Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial. <i>BMJ Open</i> , 2022, 12, e059872.	1.9	6
3	Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 45.	5.2	16
4	Abstract CT006: Phase 1b expansion trial of the safety and efficacy of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor elimusertib in advanced solid tumors with DNA damage response (DDR) defects. <i>Cancer Research</i> , 2022, 82, CT006-CT006.	0.9	8
5	Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies. <i>Cancer</i> , 2022, 128, 3185-3195.	4.1	10
6	First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors. <i>Cancer Discovery</i> , 2021, 11, 80-91.	9.4	148
7	Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. <i>British Journal of Cancer</i> , 2021, 124, 574-580.	6.4	27
8	Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 438-446.	7.0	21
9	SARS-CoV-2 vaccination and phase 1 cancer clinical trials. <i>Lancet Oncology</i> , The, 2021, 22, 298-301.	10.7	11
10	Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2021, 125, 510-519.	6.4	59
11	Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2021, 125, 520-527.	6.4	37
12	Abstract CT136: NUC-7738, a novel ProTide transformation of 3'-deoxyadenosine, in patients with advanced solid tumors. , 2021, , .		1
13	Upregulation of C/EBPβ Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5961-5978.	7.0	47
14	The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical Trial. <i>Clinical Cancer Research</i> , 2021, 27, 6500-6513.	7.0	16
15	Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours. <i>British Journal of Cancer</i> , 2020, 123, 1360-1369.	6.4	10
16	MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBPβ, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial. <i>Clinical Cancer Research</i> , 2020, 26, 3936-3946.	7.0	86
17	First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor. <i>British Journal of Cancer</i> , 2020, 123, 525-533.	6.4	46
18	A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965. <i>British Journal of Cancer</i> , 2020, 122, 1141-1145.	6.4	19

#	ARTICLE	IF	CITATIONS
19	Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2019, 20, 701-710.	10.7	50
20	Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial. , 2019, 7, 30.		68
21	Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1 trial. <i>Lancet Oncology, The</i> , 2019, 20, 383-393.	10.7	131
22	Chronic cardiovascular toxicity in the older oncology patient population. <i>Journal of Geriatric Oncology</i> , 2019, 10, 685-689.	1.0	7
23	Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial. <i>Oncolmmunology</i> , 2018, 7, e1433516.	4.6	31
24	The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small Cell Lung Cancer and in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 474-484.	2.0	41
25	A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2017, 116, 884-892.	6.4	69
26	SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting. <i>British Journal of Cancer</i> , 2017, 117, 938-946.	6.4	18
27	A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers. <i>Targeted Oncology</i> , 2017, 12, 655-661.	3.6	14
28	Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma. <i>Future Oncology</i> , 2017, 13, 175-184.	2.4	29
29	Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study. <i>Experimental Hematology and Oncology</i> , 2017, 6, 27.	5.0	10
30	A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours. <i>European Journal of Cancer</i> , 2016, 68, 1-10.	2.8	9
31	The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 113-125.e5.	1.2	133
32	Imagestream detection and characterisation of circulating tumour cells – A liquid biopsy for hepatocellular carcinoma?. <i>Journal of Hepatology</i> , 2016, 65, 305-313.	3.7	98
33	Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. <i>British Journal of Cancer</i> , 2016, 114, 723-730.	6.4	132
34	A Phase 1 Study Evaluating Pharmacokinetics (PK) and Safety of Carfilzomib in Patients with Advanced Malignancies and Varying Degrees of Hepatic Impairment (HI). <i>Blood</i> , 2016, 128, 4496-4496.	1.4	0
35	PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues – A population pharmacokinetic/pharmacodynamic analysis of rucaparib. <i>Clinical Pharmacology in Drug Development</i> , 2015, 4, 89-98.	1.6	4
36	Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. <i>Lancet Oncology, The</i> , 2015, 16, 716-728.	10.7	325

#	ARTICLE	IF	CITATIONS
37	Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker. <i>Clinical Lung Cancer</i> , 2015, 16, 348-357.	2.6	14
38	A Multicenter Phase I Study of Pazopanib in Combination with Paclitaxel in First-Line Treatment of Patients with Advanced Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 461-469.	4.1	28
39	Dose-Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study. <i>Clinical Cancer Research</i> , 2014, 20, 5663-5671.	7.0	15
40	Phase 1 study of the PARP inhibitor E7449 as a single agent in patients with advanced solid tumors or B-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, e19531-e19531.	1.6	3
41	A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 93-101.	2.3	30
42	Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , 2007, 13, 6187-6194.	7.0	226